Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 258

Sort by

Sort Order Select

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia

Blood blood.2024027170.

https://doi.org/10.1182/blood.2024027170

Published: 2025

Includes: Supplemental data

Journal Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson, Kristen B. McCullough, Betsy R. LaPlant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (23): 2456–2461.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Mehrdad Hefazi, James M. Foran, Kebede Begna, Cecilia Y. Arana Yi, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2024-198757

Published: 2024

Journal Articles

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Masooma S Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2024-193119

Published: 2024

Journal Articles

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Maymona Abdelmagid, Kaaren K. Reichard, Cinthya Zepeda Mendoza, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2024-193120

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Terra L. Lasho, Jenna A. Fernandez, Jeong-Heon Lee, Linh D. Pham, Huihuang Yan, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Joseph Collard, Claes Wahlestedt, Mrinal M. Patnaik, Moritz Binder

Blood (2024) 144 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2024-204070

Published: 2024

Journal Articles

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Naseema Gangat, Giuseppe Gaetano Loscocco, Patricia Carey, Priyansh Faldu, Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Animesh D. Pardanani, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Alessandro Maria Vannucchi, Ayalew Tefferi, Paola Guglielmelli

Blood (2024) 144 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2024-204138

Published: 2024

Journal Articles

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2024-208890

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

Journal Articles

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Anuya A. Natu, Clifford M. Csizmar, Terra L. Lasho, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2024-209236

Published: 2024

Journal Articles

PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

Saubia Fathima, Ali Alsugair, Anuya A. Natu, Clifford M. Csizmar, Mark Gurney, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Kaaren K. Reichard, Rong He, Animesh D. Pardanani, Naseema Gangat, Mrinal M. Patnaik, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 4586.

https://doi.org/10.1182/blood-2024-206007

Published: 2024

Journal Articles

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Blood (2024) 144 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2024-204334

Published: 2024

Journal Articles

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients with Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

Patricia Carey, Animesh D. Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6662.

https://doi.org/10.1182/blood-2024-199246

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients with Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only